Combination Therapies and Personalized Medicine
Key Techniques in Microbiology
Key Elements for Plant Nutrition
Gene Therapy
Group Therapy
Cancer Therapies
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Jan 31, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Gabriele Gamerith1, Florian Kocher1, Jakob Rudzki1
1Department of Internal Medicine V (Hematology and Oncology), Medical University of Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria.
ASCO 2018 highlighted immune checkpoint blockade (ICB) and combination therapies as key advances in non-small cell lung cancer (NSCLC) treatment. Biomarker research is evolving, with blood-based tests showing promise for personalized NSCLC therapy.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: